"Morpholines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D009025
|
| MeSH Number(s) |
D03.383.533.640
|
| Concept/Terms |
Morpholines- Morpholines
- Tetrahydro-1,4-Oxazines
- Tetrahydro 1,4 Oxazines
|
Below are MeSH descriptors whose meaning is more general than "Morpholines".
Below are MeSH descriptors whose meaning is more specific than "Morpholines".
This graph shows the total number of publications written about "Morpholines" by people in this website by year, and whether "Morpholines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 3 | 3 |
| 2002 | 1 | 4 | 5 |
| 2003 | 0 | 2 | 2 |
| 2004 | 2 | 1 | 3 |
| 2005 | 0 | 5 | 5 |
| 2006 | 1 | 5 | 6 |
| 2007 | 1 | 1 | 2 |
| 2008 | 1 | 2 | 3 |
| 2009 | 0 | 4 | 4 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 1 | 2 |
| 2012 | 2 | 1 | 3 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 2 | 2 |
| 2015 | 2 | 3 | 5 |
| 2016 | 0 | 3 | 3 |
| 2018 | 0 | 2 | 2 |
| 2019 | 1 | 1 | 2 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Morpholines" by people in Profiles.
-
PIKfyve, expressed by CD11c-positive cells, controls tumor immunity. Nat Commun. 2024 Jun 28; 15(1):5487.
-
The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma. Nat Commun. 2021 11 09; 12(1):6468.
-
Baloxavir for the treatment of Influenza in allogeneic hematopoietic stem cell transplant recipients previously treated with oseltamivir. Transpl Infect Dis. 2020 Aug; 22(4):e13336.
-
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020 05; 21(5):671-684.
-
A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer. Head Neck. 2019 11; 41(11):3842-3849.
-
Repair-independent functions of DNA-PKcs protect irradiated cells from mitotic slippage and accelerated senescence. J Cell Sci. 2019 07 01; 132(13).
-
HTX-019: polysorbate 80- and synthetic surfactant-free neurokinin 1 receptor antagonist for chemotherapy-induced nausea and vomiting prophylaxis. Future Oncol. 2019 Jan; 15(3):241-255.
-
Pre-Ventricular Assist Device Palliative Care Consultation: A Qualitative Analysis. J Pain Symptom Manage. 2019 01; 57(1):100-107.
-
PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma. Sci Rep. 2016 09 13; 6:32992.
-
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016 Jul 14; 375(2):134-42.